The AstraZeneca PLC ADR AZN advanced 2.35% to $73.92 Thursday, on what proved to be an all-around grim trading session for ...

Bernstein analyst Florent Cespedes maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...

Bearish flow noted in AstraZeneca (AZN) with 10,034 puts trading, or 5x expected. Most active are Apr-25 72 puts and Apr-25 70 puts, with total ...

AstraZeneca PLC closed 16.13% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...

Speaking to the Commons business and trade select committee on Tuesday, AstraZeneca’s chairman Shaun Grady confirmed that delays in securing a £90 million government contribution led to the collapse ...

The best free logo maker is a great choice for those who need to create logos for their businesses without paying for subscriptions or licenses. I'll cut to the chase: for a free logo designer ...

Covington & Burling's London operation has advised pharmaceuticals giant AstraZeneca on its $1 billion acquisition of EsoBiotec, a Belgian biotechnology company specialising in vivo cell therapies.

AstraZeneca will leverage Alteogen’s platform technology to develop the therapies. Credit: © AstraZeneca 2025. AstraZeneca has entered an exclusive licence ...

Image credit: Kateryna Kon / Shutterstock. UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso ...

Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology. AstraZeneca capped off a hectic Monday with a ...